The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib—LUX-Lung 5 (LL5).
Martin H. Schuler
Research Funding - Boehringer Ingelheim
Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Genentech; InnoPharma ; Lilly; Merck Serono; Novartis; Pfizer; Roche; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Keunchil Park
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis; Lilly; Roche
Research Funding - AstraZeneca
Jaafar Bennouna
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Yuh-Min Chen
Honoraria - AstraZeneca; Lilly; Roche
Christos Chouaid
Honoraria - Boehringer Ingelheim
Filippo De Marinis
No relevant relationships to disclose
Ji Feng Feng
No relevant relationships to disclose
Francesco Grossi
No relevant relationships to disclose
Dong-Wan Kim
No relevant relationships to disclose
Xiaoqing Liu
No relevant relationships to disclose
Shun Lu
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U)
Janos Strausz
No relevant relationships to disclose
Yurii Vinnyk
Research Funding - Boehringer Ingelheim
Rainer Wiewrodt
Consultant or Advisory Role - Boehringer Ingelheim; Grifols; Lilly; Novartis; Roche
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Grifols; Lilly; MSD; Pfizer; Roche
Research Funding - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; Roche
Caicun Zhou
Consultant or Advisory Role - Boehringer Ingelheim; Clovis; Lilly; Roche
Vikram K. Chand
Employment or Leadership Position - Boehringer Ingelheim
Bushi Wang
Employment or Leadership Position - Boehringer Ingelheim
Joo-Hang Kim
Research Funding - Boehringer Ingelheim; Lilly; Pfizer; SoIT by Roche
David Planchard
Consultant or Advisory Role - Boehringer Ingelheim